Intracranial Aneurysm Market Size and Share
Market Overview
| Study Period | 2019 - 2030 |
|---|---|
| Market Size (2025) | USD 1.72 Billion |
| Market Size (2030) | USD 2.74 Billion |
| Growth Rate (2025 - 2030) | 9.90% CAGR |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0. |
|
Intracranial Aneurysm Market Analysis by Mordor Intelligence
The intracranial aneurysm treatment devices market size stands at USD 1.72 billion in 2025 and is forecast to reach USD 2.74 billion by 2030, advancing at a 9.9% CAGR. Growth is powered by rapid uptake of minimally invasive endovascular techniques, rising incidental detection of unruptured aneurysms through routine brain imaging, and a vibrant pipeline of AI-enabled and robotic platforms. Fourth-generation flow diverters that deliver 81.7% six-month occlusion rates, intrasaccular flow disruptors that eliminate the need for parent-vessel deployment, and surface-engineered nano-coils are shifting clinical preferences toward technology-intensive solutions. Hospitals still account for most procedures, yet the outpatient migration to ambulatory surgical centers is accelerating as reimbursement models reward lower-cost settings and robotics reduce operator fatigue. Regionally, North America preserves leadership on the back of early technology adoption, while Asia-Pacific’s demographic tailwinds make it the fastest-expanding geography in the intracranial aneurysm treatment devices market.
Key Report Takeaways
- By device type, embolization coils led with 38.2% revenue share of the intracranial aneurysm treatment devices market in 2024; flow diverters are projected to post the fastest 14.0% CAGR to 2030.
- By aneurysm type, ruptured cases captured 10.5% CAGR, outpacing the unruptured segment in the intracranial aneurysm treatment devices market.
- By end user, hospitals retained 68.1% of the intracranial aneurysm treatment devices market size in 2024, while ambulatory surgical centers are on track for an 8.8% CAGR through 2030.
- By geography, North America held 41.3% revenue share in 2024, whereas Asia-Pacific is forecast to rise at an 8.2% CAGR in the intracranial aneurysm treatment devices market.
Global Intracranial Aneurysm Market Trends and Insights
Drivers Impact Analysis
| Driver | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Rising Demand For Minimally-Invasive Endovascular Procedures | +2.80% | Global, with North America & EU leading adoption | Medium term (2-4 years) |
| Growing Prevalence Of Unruptured Aneurysm Detection Through Incidental Brain Imaging | +2.10% | Global, particularly developed markets | Long term (≥ 4 years) |
| Age-Linked Hypertension & Smoking Prevalence In Developing Economies | +1.60% | APAC core, spill-over to MEA | Long term (≥ 4 years) |
| FDA Breakthrough-Device Designations Accelerating Device Approvals | +1.40% | North America & EU, with global spillover | Short term (≤ 2 years) |
| Emergence Of AI-Guided Robotic Neuro-Intervention Platforms | +1.20% | North America & EU initially, expanding globally | Medium term (2-4 years) |
| Venture Funding Surge Into Nano-Coil Surface Engineering Start-Ups | +0.80% | Global, concentrated in innovation hubs | Medium term (2-4 years) |
| Source: Mordor Intelligence | |||
Rising Demand for Minimally Invasive Endovascular Procedures
Outpatient-ready flow diverters and AI-guided robotic systems have made complex neurovascular work feasible in ambulatory environments. In 2024, US ambulatory surgical centers treated 3.3 million Medicare beneficiaries, signaling a decisive swing away from inpatient neurosurgery.[1]Medicare Payment Advisory Commission, “2024 Data Book: Health Care Spending and the Medicare Program,” medpac.gov Robotic deployments such as the CorPath GRX platform secured 100% technical success and lower radiation exposure, encouraging health systems to open dedicated outpatient neuro-intervention suites.
Growing Prevalence of Unruptured Aneurysm Detection Through Incidental Brain Imaging
High-resolution MRI and CT angiography now uncover countless asymptomatic lesions, expanding the treatable population. AI algorithms like Viz ANEURYSM, cleared by the FDA in 2024, standardize reading protocols and reduce inter-observer variability.[2]U.S. Food and Drug Administration, “510(k) Premarket Notification – Viz ANEURYSM,” fda.gov The surge strains risk-stratification workflows and stimulates demand for decision-support tools bundled with next-generation devices.
Age-Linked Hypertension & Smoking Prevalence in Developing Economies
Urbanization in China, India, and Southeast Asia pushes hypertension and smoking rates higher, translating into more aneurysm presentations in younger cohorts. National programs such as “Healthy China 2030” dedicate budget lines for stroke prevention, opening the door for value-tier devices designed for cost-sensitive markets.
FDA Breakthrough-Device Designations Accelerating Device Approvals
Regulatory acceleration mechanisms are speeding up device development timelines, giving companies that navigate expedited approval pathways a competitive edge. In 2024, CereVasc's eShunt System earned breakthrough device status, showcasing the FDA's focus on fast-tracking innovative neurovascular technologies for critical clinical needs, Medical Device Network, 2024. Additionally, new quality system regulation amendments, effective February 2026, will standardize manufacturing requirements. While this may benefit larger companies with established systems, smaller innovators could face challenges meeting stricter compliance standards FDA, 2024.
Restraints Impact Analysis
| Restraint | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| High Device & Procedural Costs With Limited Reimbursement | -1.80% | Global, particularly emerging markets | Medium term (2-4 years) |
| Shortage Of Dual-Trained Endovascular Neurosurgeons In Emerging Markets | -1.20% | APAC, MEA, Latin America | Long term (≥ 4 years) |
| Device-Related Thrombo-Embolic Complications Requiring Lifelong DAPT | -0.90% | Global | Short term (≤ 2 years) |
| Supply-Chain Dependence On Platinum & Cobalt – Price Volatility Exposure | -0.70% | Global manufacturing hubs | Medium term (2-4 years) |
| Source: Mordor Intelligence | |||
High Device & Procedural Costs With Limited Reimbursement
US CMS pass-through codes remain restrictive for cutting-edge implants, while Korea reimburses flow diverters only for large aneurysms, capping penetration.[3]Centers for Medicare & Medicaid Services, “2024 Hospital Outpatient Prospective Payment System Final Rule,” cms.govManufacturers now pair launches with health-economic dossiers and risk-sharing contracts to prove lifetime value to payers.
Shortage Of Dual-Trained Endovascular Neurosurgeons in Emerging Markets
Training gaps slow technology diffusion despite device availability. Japan’s strict credentialing regime underscores the proficiency required; emerging economies lack such infrastructure, prompting suppliers to fund regional centers of excellence and simulator-based curricula.
Segment Analysis
By Device Type: Flow Diverters Redefine Hemodynamic Treatment
Flow diverters occupy the fastest lane, expanding at a 14.0% CAGR and steadily eroding coil dominance. The Pipeline Vantage recorded 81.7% six-month occlusion in pivotal studies, while hydrophilic-coated variants cut thrombotic events to 4.7% and achieved 92.3% long-term closure. Platinum remains central, forming 30-40% of material content for its radiopacity and biocompatibility.
The segment’s outlook is strengthened by intrasaccular disruptors such as WEB 17 that produce 86.5% complete occlusion in ruptured aneurysms after one year. As a result, global purchasers are reallocating capital budgets toward devices promising fewer retreatments and shorter learning curves, uplifting the intracranial aneurysm treatment devices market.
Note: Segment shares of all individual segments available upon report purchase
By End User: Ambulatory Centers Capture Outpatient Momentum
Hospitals still generate most revenue, yet ambulatory surgical centers grow at 8.8% CAGR as robotics shrinks equipment footprints and reimbursement favors same-day discharge. Neuro-interventional case volumes in US outpatient centers climbed sharply in 2024, reflecting payer endorsement of cost-efficient settings.
Manufacturers are therefore engineering single-operator platforms with pre-loaded cartridges to suit ambulatory workflows. The resulting productivity gains reinforce the structural shift and enlarge the intracranial aneurysm treatment devices market size within outpatient channels.
Note: Segment shares of all individual segments available upon report purchase
Geography Analysis
North America sustains a 41.3% revenue share, aided by FDA breakthrough pathways and payer openness to premium implants. Corporate M&A remains brisk, exemplified by Stryker’s USD 4.9 billion Inari acquisition that broadens access to venous and neurovascular segments. Nonetheless, device review staffing cuts at the FDA risk stretching approval queues, tempering near-term acceleration.
Asia-Pacific is the fastest-growing region with an 8.2% CAGR. China’s NMPA reforms and the “Healthy China 2030” mandate increase funding for cerebrovascular care, whereas Japan’s PMDA provides predictable, science-based approvals. Growing middle-class demand, combined with policy support, expands the intracranial aneurysm treatment devices market, though heterogeneous reimbursement keeps price tiers wide.
Europe’s MDR environment remains rigorous, emphasizing long-term safety data. Penumbra’s 2024 CE marks for aspiration and coil systems show that novel devices can still navigate the pathway when supported by robust clinical evidence. Brexit-related divergence obliges firms to budget separately for UK conformity, nudging some smaller entrants to prioritize EU27 first.
Competitive Landscape
Large multinationals dominate core portfolios, yet the market stays moderately concentrated as new entrants inject technological flair. Medtronic logged USD 2.317 billion neuroscience sales in Q1 FY25, crediting AI-enabled launches for momentum. Boston Scientific’s USD 1.26 billion Silk Road Medical purchase complements carotid protection assets and signals adjacency convergence.
Venture-backed challengers secure sizable rounds: Route 92 Medical raised USD 50 million to refine aspiration catheters, while Spryte Medical earned breakthrough status for OCT-guided brain imaging. Competition now hinges on delivering data-rich, operator-friendly systems that satisfy value-based contracts, pushing the intracranial aneurysm treatment devices market toward outcome-driven procurement.
Long-term supply stability remains a concern as platinum and cobalt price swings disrupt cost structures. Players with backward-integration or diversified sourcing gain resilience, especially when global macro shifts unsettle mining output. Simultaneously, quality-system regulation amendments effective in 2026 may advantage firms with mature compliance frameworks, potentially raising entry barriers for smaller innovators and shaping the future structure of the intracranial aneurysm treatment devices market.
Intracranial Aneurysm Industry Leaders
-
Stryker
-
B. Braun Melsungen AG
-
Medtronic
-
Terumo Corporation
-
MicroPort Scientific Corporation
- *Disclaimer: Major Players sorted in no particular order
Recent Industry Developments
- February 2025: Stryker completed its USD 4.9 billion acquisition of Inari Medical, enlarging its peripheral vascular footprint.
- February 2025: Johnson & Johnson initiated plans to divest its Cerenovus stroke business for USD 1 billion.
- November 2024: Medtronic gained FDA approval for the Affera Mapping and Ablation System and launched the Evolut FX+ TAVR device.
- September 2024: MicroVention was rebranded to Terumo Neuro to reflect an expanded strategy.
Global Intracranial Aneurysm Market Report Scope
As per the scope, an intracranial aneurysm, also known as cerebral or brain aneurysm, is a bulging, weakened area in the wall of an artery in the brain, resulting in abnormal widening and ballooning. The intracranial aneurysm market is segmented by type (endovascular coiling, surgical clipping, flow diverters), end-user (hospitals, ambulatory surgical centers, and other end-users), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (USD million) for the above segments.
| Embolization Coils |
| Flow Diverters |
| Intrasaccular Flow Disruptors |
| Intracranial Stents & Balloons |
| Aneurysm Clips |
| Others |
| Hospitals |
| Ambulatory Surgical Centers |
| Specialty Neurosurgical Centers |
| North America | United States |
| Canada | |
| Mexico | |
| Europe | Germany |
| United Kingdom | |
| France | |
| Italy | |
| Spain | |
| Rest of Europe | |
| Asia Pacific | China |
| Japan | |
| India | |
| South Korea | |
| Australia | |
| Rest of Asia Pacific | |
| Middle East & Africa | GCC |
| South Africa | |
| Rest of Middle East & Africa | |
| South America | Brazil |
| Argentina | |
| Rest of South America |
| By Device Type | Embolization Coils | |
| Flow Diverters | ||
| Intrasaccular Flow Disruptors | ||
| Intracranial Stents & Balloons | ||
| Aneurysm Clips | ||
| Others | ||
| By End-user | Hospitals | |
| Ambulatory Surgical Centers | ||
| Specialty Neurosurgical Centers | ||
| By Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Europe | Germany | |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Asia Pacific | China | |
| Japan | ||
| India | ||
| South Korea | ||
| Australia | ||
| Rest of Asia Pacific | ||
| Middle East & Africa | GCC | |
| South Africa | ||
| Rest of Middle East & Africa | ||
| South America | Brazil | |
| Argentina | ||
| Rest of South America | ||
Key Questions Answered in the Report
What is the current value of the intracranial aneurysm treatment devices market?
It is valued at USD 1.72 billion in 2025, with a projected rise to USD 2.74 billion by 2030.
Which device segment is growing fastest?
Flow diverters are expanding at a 14.0% CAGR due to high occlusion rates and newer coated designs.
Why are ambulatory surgical centers important to market growth?
They offer lower-cost, outpatient settings that align with payer incentives and robotics-enabled minimally invasive procedures, driving an 8.8% CAGR.
What geographic region shows the highest growth potential?
Asia-Pacific leads with an 8.2% CAGR, supported by demographic shifts and supportive policy frameworks.
How are FDA breakthrough designations influencing the market?
They shorten approval timelines, allowing innovative devices to reach clinicians faster and intensifying competitive pressure.
Page last updated on:
